Matthew Mcmanus
CIK 1908268 · View on SEC EDGAR ↗
First SEC filing: Feb. 2, 2022 · Latest: Feb. 2, 2022
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 19, 2022 | AZTA | P | 8,625 | $58.15 | $501,544 | 29,467 Direct | +41.38% | Acquired | -39.3% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 1, 2026 | TECH | Restricted Stock Units | Common Stock (4,621) | — | — | 4,621 | Disposed |
| Aug. 15, 2025 | TECH | Stock Option (Right to Buy) | Common Stock (24,614) | $53.60 | Aug. 15, 2035 | 24,614 | Acquired |
| Aug. 15, 2025 | TECH | Restricted Stock Units | Common Stock (9,622) | — | — | 9,622 | Acquired |
| Aug. 15, 2025 | TECH | Performance Restricted Stock Units | Common Stock (19,243) | — | — | 19,243 | Acquired |
| Aug. 15, 2025 | TECH | Restricted Stock Units | Common Stock (2,637) | — | — | 2,637 | Disposed |
| Feb. 1, 2025 | TECH | Restricted Stock Units | Common Stock (4,620) | — | — | 4,620 | Disposed |
| Aug. 15, 2024 | TECH | Performance Restricted Stock Units | Common Stock (15,825) | — | — | 15,825 | Acquired |
| Aug. 15, 2024 | TECH | Stock Option (Right to Buy) | Common Stock (21,320) | $74.91 | Aug. 15, 2034 | 21,320 | Acquired |
| Aug. 15, 2024 | TECH | Restricted Stock Units | Common Stock (7,912) | — | — | 7,912 | Acquired |
| Aug. 15, 2024 | TECH | Performance Restricted Stock Units | Common Stock (15,818) | — | — | 15,818 | Acquired |
| Feb. 1, 2024 | TECH | Stock Option (Right to Buy) | Common Stock (15,902) | $68.54 | Feb. 1, 2031 | 15,902 | Acquired |
| Feb. 1, 2024 | TECH | Stock Option (Right to Buy) | Common Stock (7,951) | $68.54 | Feb. 1, 2031 | 7,951 | Acquired |
| Feb. 1, 2024 | TECH | Restricted Stock Units | Common Stock (13,861) | — | — | 13,861 | Acquired |
| Feb. 1, 2024 | TECH | Restricted Stock Units | Common Stock (2,888) | — | — | 2,888 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 2, 2022 | AZTA | Common Stock | — | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
TECH
President, Diagnostics and Genomics| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $253,846 | — | — | — | $124,027 | — | $6,980 | $1,994,642 |
| 2023 | — | — | — | — | — | — | — | — |
| 2022 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.